Open AccessHepatitis D virus and liver transplantation: Indications and outcomes
Author(s) -
Haris Muhammad,
Aniqa Tehreem,
Muhammad M. Hammami,
Peng–Sheng Ting,
Ramzan Idilman,
Ahmet Gürakar
Publication year - 2021
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v13.i3.291
Subject(s) - medicine , liver transplantation , hepatitis c virus , virology , virus , transplantation , intensive care medicine , gastroenterology , immunology
Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Liver transplantation (LT) is the only treatment option for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to coinfection with HDV. As LT for HDV and hepatitis B virus coinfection is uncommon in the United States, most data on the long-term impact of LT on HDV are from international centers. In this review, we discuss the indications and results of LT with treatment options in HDV patients.